The widely publicized start-up company 23andMe, Inc. markets its “personal genome service product” as providing reports on hundreds of diseases and conditions that enable users to “take steps toward mitigating serious...more
In this issue:
- It’s Easier Being Green
- Off-Label Marketing Protected by First Amendment
- Understanding New Restrictions on Advertising GI Bill Benefits
- FTC Looks at "The Big Picture"
On December 3, 2012, the United States Court of Appeals for the Second Circuit, in a 2-1 opinion, vacated the criminal conviction of a pharmaceutical sales representative for promoting off-label uses of a particular drug....more